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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
“Hyaluronic Acid intra articular injection is better than Corticosteroid intra articular injection at
reducing pain in patients with knee osteoarthritis.”
STUDY DESIGN: Review of three double-blind, randomized control trials published between
2014 and 2016. All studies were published in English language in peer reviewed journals.
DATA SOURCES: All three randomized control trials were found via PubMed.
OUTCOMES MEASURED: The primary outcomes measured by the patient and investigator
being improvement of knee pain severity, knee function, and range of motion after hyaluronic
acid intra articular (IA) injection versus corticosteroid intra articular injection.
RESULTS: Leighton et al demonstrated that NASHA hyaluronic acid as a single injection intraarticular treatment is a valuable treatment for knee osteoarthritis (OA), providing effectiveness
that was non-inferior to methylprednisolone. It also indicated that the effect of NASHA
hyaluronic acid as a single injection intra-articular treatment is longer lasting, with significantly
improved pain response at 26 weeks compared to methylprednisolone with a p value of <0.05.
Tammachote et al demonstrated that patients who took triamcinolone acetonide had similar
improvement in knee pain. Both hylan G-F 20 and triamcinolone acetonide are both effective at
reducing pain from knee OA and there is not a significant difference in pain reduction between
the two groups with a p value >0.05. Bisicchia et al demonstrated that HYADD is effective at
reducing pain from knee OA and more effective than corticosteroids with a p value <0.0001.
CONCLUSIONS: It can be concluded there is conflicting evidence whether or not hyaluronic
acid intra-articular injection is better than corticosteroid intra articular injection at reducing pain
in patients with knee OA. Based upon this evidence, both corticosteroids and hyaluronic acid
intra articular injections are effective at reducing pain in patients with knee OA with no clear-cut
answer if one is superior to the other. It was shown, however, that hyaluronic acid intra articular
injections are possibly better long term in that they are longer lasting than corticosteroid intra
articular injections.
KEY WORDS: Osteoarthritis, Hyaluronic Acid, Corticosteroid
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INTRODUCTION
Osteoarthritis (OA) is a degenerative joint disease in which all of the structures of the
joint have undergone pathological changes. It is the most common form of joint disease as well
as the leading cause of disability in the elderly. By 2013, knee OA contributed more than $27
billion in health care expenditures annually.1 A study in 2012 demonstrated that OA cost the U.S.
economy more than $100 billion annually.1 In 2010, there were more than 100 million outpatient
visits due to arthritis and OA accounts for more than 25 percent of all arthritis-related health care
visits.1
The exact cause of OA is unknown but is thought to be caused by a combination of
systemic, intrinsic, and loading factors such as: age, gender, race, obesity, repetitive use, and
previous damage. The presentation of OA is described as a gradual onset of joint pain that
increases with activity and is relieved with rest. There is morning stiffness usually not lasting
longer than 30 minutes as well as a feeling of joint instability.
Treating OA varies from person to person mainly relying on reducing the pain caused by
the pathological changes occurring within the joint structures. Unfortunately, there is not any
treatment to prevent OA from occurring or slowing down the progression of it.
Nonpharmacological treatment includes avoiding weight bearing exercises causing pain, physical
therapy, using braces, heat and cold compresses, as well as weight loss. Pharmacological
treatment involves Acetaminophen, NSAIDs, Capsaicin topical cream, topical NSAIDs, Opioids,
and Intra-articular injections (Glucocorticoids and Hyaluronic acid). The only cure for OA is a
joint replacement surgery.
Though surgery is the only cure for OA, it is a highly invasive and aggressive treatment
that patients prefer to keep as their last resort. Also, there are risks to constant NSAID use like
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peptic ulcer disease, cardiovascular complications, and gastric ulcers. In addition, long term
corticosteroid use carries complications such as osteoporosis, cataracts, glaucoma, thinning of
the skin, hypertension, diabetes, and weight gain. Considering that OA is a chronic, degenerative
joint disease, it is pivotal to find a way to treat it in a safer, long term approach. Reducing pain in
patients with OA, allowing them to live without constant discomfort, and doing so without
invasive and side effect filled treatments is an attainable goal. According to Bowman et al, there
are multiple hyaluronic acid products approved by the FDA currently and hyaluronic acid
treatment shows great potential in lubrication, anti-inflammatory, and chondroprotective.6
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Hyaluronic
Acid intra articular injection is better than Corticosteroid intra articular injection at reducing pain
in patients with knee osteoarthritis.”
METHODS
Three randomized controlled trials were used in this review. The selected population of
interest were patients greater than 30 years of age with diagnosed and symptomatic knee pain.
The intervention in the three randomized controlled trials was hyaluronic acid intra articular
injection. The treatment group receiving hyaluronic acid intra articular injection was compared
to the experimental group receiving corticosteroid intra articular injection. The primary outcomes
measured by the patient and investigator were improvement of knee pain severity, knee function,
and range of motion after hyaluronic acid intra articular injection versus corticosteroid intra
articular injection. The types of studies used were three randomized controlled trials comparing
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hyaluronic acid intra articular injection to corticosteroid intra articular injection at reducing pain
in patients with knee OA.
The keywords Hyaluronic acid intra articular injection and corticosteroid intra articular
injection and OA were searched on PubMed and selected based upon the relevance to my clinical
question and if they had patient oriented outcomes (POEMS: Patient Orientated Evidence that
Matters). All of the articles were published in English and published in peer reviewed journals.
The inclusion criteria were studies that were RCTs published after 2008 and exclusion criteria
was age less than 30 years old and Intra-articular injections in the last 12 months or surgery in
either knee within the preceding 12 months. The statistics used and reported in this selective
based medicine review were p- values, mean change from baseline, and number needed to treat
(NNT).
Table 1- Demographics & Characteristics of Included Studies
Study

Type

# Pts

Leighton3
(2014)

RCT

442

Tammachote
4
(2016)

RCT

110

Age
(yrs)
35–80

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

Men and women aged 35-80
2
with BMI of <40 kg/m ,
ability to walk 50 m unaided,
Unilateral knee pain meeting,
WOMAC pain score of 7-17,
Radio-graphically verified
OA.

Participants with clinically
detectable knee effusion,
clinically significant
contralateral knee OA
(WOMAC pain score >3),
clinically significant pain in
joints other than the knee, IA
steroid injection into the study
knee within the preceding 3
months, IA HA injection into
the study knee within the
preceding 9 months, use of
systemic glucocorticosteroids
within the preceding 3 months,
Arthroscopy or other surgical
procedure in the study knee
within the preceding 12
months.

10

NASHA hyaluronic
acid gel as singleinjection intraarticular
methylprednisolone
acetate intra-articular
injection

The
mean
age of
the
patient
s in the

Symptomatic knee OA,
dissatisfaction with
conservative treatment, no
lumbar spondylosis with
radiculopathy, good
cognition, ability to

Participants with an allergy to
any of the medications used,
bone-on-bone arthritis on any
radiograph, varus or valgus
deformity of >5 degrees,
previous fracture or surgical

11

Hyaluronic acid
(hylan G-F 20) intra
articular injection and
triamcinolone
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Bisicchia5
(2016)

RCT

150

hylan
G-F 20
group
was 63
years
(range,
46 to
77
years).
The
mean
age of
the
patient
s in the
triamci
nolone
acetoni
de
group
was 61
years
(range,
47 to
81
years),

understand the study protocol,
agreement to participate.

procedure of knee, previous
intra-articular injection in the
ipsilateral knee in the past 6
months, current infection in
the affected limb.

HYAD
D4
group
(mean
age
71.5±1
0.6
years),
CS
group
(mean
age
68.6±9.
9
years)

Male and female walking
patients older than 45, single
symptomatic knee, KellgrenLawrence (29) grade 2–3 knee
osteoarthritis and a VAS for
pain ≥3.

Participants with grade 1 or 4
OA, according to KellgrenLawrence (29), symptoms in
both knees, a varus or valgus
deformity greater than 10
degrees, flexion contracture
greater that 15 degrees,
ligamentous instability or
meniscal tears, NSAIDSs used
in the last 30 days, Intraarticular injections in the last
12 months; septic,
inflammatory or crystal
arthritis, previous surgeries in
the last 6 months, physical
therapy in the last 30 days.

acetonide intraarticular injection

0

HYADD 4 intra
articular injection and
methylprednisolone
intra articular
injection

OUTCOMES MEASURED
The primary outcomes measured were knee pain severity, knee function, and range of
motion after using of hyaluronic acid intra articular injection versus corticosteroid intra articular
injection. This was done via the visual analog scale (VAS) and Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC).
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RESULTS
This selective evidence based medicine review evaluates hyaluronic acid (HA) intra
articular (IA) injections for the treatment of OA in comparison to corticosteroid intra articular
injections. All three of these studies were randomized controlled trials. Leighton et al and
Tammachote et al were both double blind clinical trials. Bisicchia et al was a single center, single
blind, clinical trial.
Leighton et al is an active-controlled, double-blind, non-inferiority clinical trial that
evaluates NASHA HA for the treatment of OA in order to prove that it is not inferior at treating
pain in comparison to methylprednisolone (MPA). In total, 442 patients with unilateral pain in
their knee from OA entered this clinical trial.3 The patients were randomized 1:1 to receive either
hyaluronic acid or MPA intra articular injection. All of the patients were followed and evaluated
for 26 weeks. At that time, the patients returned to the clinic and were given NASHA hyaluronic
acid and then reevaluated in an additional 26 weeks. The initial 26-week period was a completely
blinded study. The following 26-week period was an unblinded study with NASHA hyaluronic
acid treatment only.3 Only the first 26-week period will be discussed throughout this review.
There were 15 sites in Canada, 4 in the UK, and 5 in Sweden. The follow up consisted of a
screening visit, a baseline visit at which the IA injections were administered, telephone calls at 2
and 4 weeks to evaluate safety and concomitant medication use, and clinic visits at 6, 12, 18 and
26 weeks to determine effectiveness or any safety issues. Rescue medication
with acetaminophen was allowed at up to 3 g per day.3 Arthralgia was the most common
treatment-related complaint in both study groups. Most of the patients receiving the injections
had side effects within the first 3 days with them being resolved in 2-3 weeks. Primary
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effectiveness analysis was measured using the WOMAC pain scale. At 26-weeks the data
portrayed a responder rate of NASHA at 54% and MPA at 44% with a p-value of 0.043 which is
a significant p value being <.05. This data shows that NASHA is non-inferior to MPA and that
NASHA has more long-term effects whereas MPA declined throughout the study. Number
needed to treat (NNT) was calculated as 10 which is a large treatment effect. This value means
that for every 10 participants who took NASHA hyaluronic acid as a single injection intraarticular treatment, there was one more person who had a pain reduction than in the group taking
methylprednisolone. In conclusion, this study showed that NASHA hyaluronic acid IA is an
effective and safe treatment for OA and is non-inferior to MPA.3
Table 2: Patient Outcomes as Evaluated by Responder Rate in WOMAC pain scale
Leighton et al3

NASHA
MPA
P-VALUE

RESPONDER RATE AT 12
WEEKS
44.6%
46.2%

RESPONDER RATE AT 26
WEEKS
54%
44%
0.043

Tammachote et al is a prospective, randomized, double-blind clinical trial that compares
of hyaluronic acid (hylan G-F 20) with triamcinolone acetonide as a single intra-articular (IA)
injection for knee OA. The purpose of this clinical trial was to prove which treatment had a
better outcome in knee pain, range of motion, and knee function. Knee pain and range of motion
will be the two outcomes discussed throughout this review. In total, 110 patients entered the
clinical trial and were put into two separate groups to receive the injection; 55 in each group. The
patients were then followed for six months. All of the injections were given in an outpatient
clinic and the patients and evaluators were kept blinded.4 Knee pain was measured using the
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VAS pain scale and knee function was measured using the WOMAC index. The VAS pain scale
was completed at baseline; at days 1, 2, and 3; at weeks 1 and 2; and at months 1, 2, 3, 4, 5, and
6. The WOMAC index was completed at baseline, week 2, and months 1, 2, 3, 4, 5, and 6. At the
end of the clinical trial, 49 patients remained in the triamcinolone acetonide group and 50
remained in the hyaluronic acid group. The author did not report why the 11 patients withdrew
from the trial.4 In reference to knee pain, the triamcinolone acetonide group had significantly
better pain relief especially in the first week with a p value of 0.02. Right after the injection, the
VAS score for pain was evaluated. The mean difference between groups was 11 with a p value of
< 0.05. As time went on, the mean difference was small and not significant.4 Even though the
triamcinolone acetonide group showed more overall pain relief in the first week, both groups
showed significant pain relief after injection (p < 0.0001). Both groups had similar improvement
in knee function with a p value > 0.05. At the end of 6 months, the mean modified WOMAC
scores had significantly improved (p < 0.0001 for both) from 43 to 21 points (95% CI, 16.7 to
29.2 points) in the hylan G-F 20 group and from 39 to 21 points (95% CI, 11.0 to 24.3 points) in
the triamcinolone acetonide group. At the end of the 6 months, the mean change in VAS scores
was almost 30 points in both groups: 29 points (95% CI, 236.4 to 222.7 points) in the hylan G-F
20 group and 30 points (95% CI, 236.0 to 222.8 points) in the triamcinolone acetonide group (p
< 0.0001).4 This is a large mean change from baseline. According to Tammachote et al there
were no serious adverse effects reported throughout this clinical trial from both groups. Knee
pain and swelling were reported by one patient in the hylan G-F 20 group which was relieved
with the post injection pain medication. In conclusion, hyaluronic acid and triamcinolone
acetonide as a single IA injection for knee OA have similar outcomes in knee pain relief and
functional improvement at 6 months with a p-value = 0.81 for the WOMAC pain scale and a p-
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value of 0.60 for the VAS pain scale. Both of these p values are not statistically significant p
values. However, it was seen that triamcinolone acetonide has a quicker response on pain relief
within the first two weeks.4
Table 3: Differences in Mean Outcome Scores Between Groups4

Hylan G-F 20 Group
Triamcinolone Acetonide
Group

VAS PAIN SCALE AT 6
MONTHS
24±22

WOMAC PAIN SCALE AT
6 MONTHS
21±15

21±22

21±19

P-VALUE AT 6
MONTHS
0.60 (VAS PAIN
SCALE)
0.81 (WOMAC)

Bisicchia et al is a single-center, single blind prospective randomized controlled clinical
study that compares HA (HYADD 4) with corticosteroid (CS). All of the patients who entered
this trial were randomly assigned and either received two injections of HA or two injections of
CS. There were 53 females and 22 males in the HYADD 4 group and 50 females and 25 males in
the CS group. The patients were followed throughout an entire year and evaluated using the
WOMAC pain index and VAS pain scale. The two most common side effects reported were
discomfort during the injection and joint discomfort for about 2–3 days after the injection being
almost equal between both groups with a p value >0.05.5 All of the patients completed the
evaluation at 6 and 12 weeks. Between 12 and 26 weeks and between 26 and 52 weeks, some
patients returned back to the clinic for a new injection cycle due to a significant reduction in the
treatment effect. All of the patients that returned back were considered treatment failures and
excluded from the trial. With the exclusion of those patients, there were 72 patients in HYADD 4
group and 64 in the CS group at the 26-week evaluation. At the 26-week follow up, the HYADD
4 group reported significantly better results compared to the CS group with a p value of <0.0001
on the WOMAC pain index. At any point in time on the WOMAC pain index, patients
significantly improved compared to baseline in both groups. In reference to the VAS pain scale,
at week 26, patients in the HYADD 4 group obtained significantly better results with a p value of
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0.0004 at 26 weeks.5 At 26 weeks, the mean change from baseline for HYADD 4 was 14.1 and
the mean change from baseline for corticosteroids was 9. This is a large mean change from
baseline for both groups, however, HYADD had a larger mean change from baseline at 26
weeks. At the one year mark, both groups returned back to baseline on the WOMAC pain index
and VAS pain scale. In conclusion, HYADD 4 provided better pain relief than the Corticosteroid
group in short term, but neither had long term control of the symptoms.5
DISCUSSION
Osteoarthritis is a chronic, degenerative disease in which patients need long term pain
control. This makes treating patients safely and adequately with OA difficult. The three
randomized controlled trials discussed in this review suggest that hyaluronic acid intra articular
injection is an effective treatment for knee OA with conflicting evidence whether it is superior or
inferior to corticosteroid intra articular injection. In Leighton et al, they considered the absence
of a saline control arm being a limitation, but to add such a thing was medically unethical.3 In
Bisicchia et al was a single blind study towards the observers so the patients were informed
which treatment they would be receiving. This might have cause a bias limiting the efficacy of
the clinical trial. An additional limitation in Bisicchia et al clinical trial includes that the
evaluators did not record the BMI of the patients. Patients with higher BMIs could have had a
higher pain levels and higher failure rates due to the excess weight they have.5
CONCLUSION
In conclusion, there is conflicting evidence whether hyaluronic acid IA injection is
superior to corticosteroid IA injection for unilateral knee pain from OA. According to Leighton
et al, HA is non-inferior to corticosteroid and has a longer effect on pain relief. However,
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according to Tammachote et al, both have similar effects, with corticosteroids having a quicker
onset. According to Bisicchia et al, hyaluronic acid provides better short-term control of
symptoms and neither has more side effects than the other. All three of these trials have some
opposing results about which treatment is superior, but all three clinical trials show that both
have similar effects on knee OA at reducing pain and improving function.
Further studies are warranted to evaluate HA in the treatment of knee OA with a larger
sample size and longer follow up. It is important to factor in the amount and type of physical
activity each patient is participating in throughout the follow up period. Also, separating the
groups based upon sex could give more insight as to which population has greater benefit with
hyaluronic acid IA injection as opposed to corticosteroid IA injection.
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